Idorsia Ltd
SIX:IDIA
Idorsia Ltd
Inventory
Idorsia Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
Inventory
CHf86m
|
CAGR 3-Years
66%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Inventory
$18m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Inventory
CHf22.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Inventory
CHf11.9m
|
CAGR 3-Years
72%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Inventory
CHf923k
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's Inventory?
Inventory
86m
CHF
Based on the financial report for Sep 30, 2025, Idorsia Ltd's Inventory amounts to 86m CHF.
What is Idorsia Ltd's Inventory growth rate?
Inventory CAGR 3Y
66%
Over the last year, the Inventory growth was 8%. The average annual Inventory growth rates for Idorsia Ltd have been 66% over the past three years .
